Sangram Nag

Sangram Nag is the Team Leader of the Radiochemistry Research and Development Team at the Karolinska Institutet PET Centre and has been recognized as one of the leaders in this area of research. Due to his passion for this challenging field, he plays a direct role in the development of PET radioligands at the neuroscience division. In parallel, together with the well-regarded Professor Christer Halldin and Professor Andrea Varrone, Sangram moves academic research forwards and seeks for contacts with industry to assist the drug discovery. His duties involve managing a diverse team responsible for improving firm operations, technology application, and building innovative organizational practices. 

Also, Sangram appears to be taking adequate care of the PhD students mentoring and is of importance in helping build future science talent. His research interests are devoted to the development of new PET radioligands for the central nervous system. Moving beyond simply imaging through a one-dimensional lens of animal to human translation, Sangram was able to contribute to the publication of 61 scientific papers covering the areas of radiochemistry and molecular imaging. In particular, by being committed to introducing new imaging systems of the highest order garners Sangram’s efforts towards making a mark in precision diagnosis and therapy of central nervous system disorders to the PET radioligand field and neuroscience.

Research Interest of Sangram Nag:

The research focus of Sangram Nag lies at the intersection of neuroimaging and radiopharmaceutical development, particularly within the realm of Positron Emission Tomography (PET) for Central Nervous System (CNS) imaging. With a keen interest in advancing the field of PET radioligands, Sangram is dedicated to crafting novel radioligands tailored to target precise CNS receptors and proteins. His research objectives encompass design and synthesis strategies that prioritize optimizing radioligand properties, including binding affinity, selectivity, and brain penetrance, to enhance efficacy in CNS imaging studies.

In tandem with design efforts, Sangram’s research delves into meticulous in vitro evaluation, where radioligand-receptor interactions are scrutinized through rigorous binding studies. By assessing parameters such as affinity, selectivity, and metabolic stability, Sangram aims to anticipate radioligands' in vivo behavior accurately, laying a robust foundation for subsequent optimization and translation endeavors.

The crux of Sangram’s research lies in conducting sophisticated in vivo studies utilizing small animal PET imaging techniques to unravel essential parameters of radioligands within the CNS. These studies aim to elucidate brain penetrance, distribution patterns, and specific binding attributes within live animal models, providing comprehensive insights into radiotracer behavior post-administration. Through the strategic integration of design, in vitro evaluation, and in vivo studies, Sangram Nag’s research plan navigates the complex landscape of novel PET radioligand development for CNS imaging, contributing significantly to the advancement of precision diagnostics and therapeutic interventions in neurological disorders.